Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease - Wikidata - awgldk - TriplyDB

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

http://www.wikidata.org/entity/Q36193201

about

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A Towards personalised therapy for von Willebrand disease: a future role for recombinant products Present day management of inherited bleeding disorders in pregnancy.Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders von Willebrand Disease.Von Willebrand factor for menorrhagia: a survey and literature review.Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.Controversies in the diagnosis of Type 1 von Willebrand disease.Outcomes in Patients With Hemophilia and von Willebrand Disease Undergoing Invasive or Surgical Procedures.Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.Advances in the treatment of bleeding disorders.Current and Emerging Options for the Management of Inherited von Willebrand Disease.Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report.Discarding Occam's Razor: Atypical Bruising in Severe Hemophilia A.Women leaders in hematology: Inspirations & insights.Advances in the diagnosis and treatment of Von Willebrand disease.Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer.Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report.Von Willebrand disease in the United States: perspective from the Zimmerman program Current issues in diagnosis and treatment of von Willebrand disease Von Willebrand disease in the elderly: clinical perspectives

P2860

Q26738507-56043D25-73E2-4C67-A8EB-38BDEE1DBF0B Q26748376-E233C333-2321-4FD3-92BD-B3513AE9D705 Q30248782-803B3EF6-46A6-4FB3-9845-BC566DD11D2B Q30491320-EF8F5F06-583E-43F1-92DF-8C5C63840F6F Q33608224-DAB9EF05-1128-46F9-9328-946590183529 Q34546675-D617130D-A26D-4B8A-A275-160B973A675A Q36922153-983591C1-64DA-45B8-9B00-2099E34F3159 Q38687056-F04B0A81-7439-4C62-A991-29BF5842867E Q38690381-9C2091DB-CCA7-4CFC-8B12-E9638EDC0B2A Q38897517-17F832B9-2DBC-4DA7-AEEB-0DDB2BB09481 Q38900471-4AB0EB2C-0C5E-4E23-BE2A-8CF598A7D6F2 Q38945123-9FA8E080-4FE5-4C9C-BB81-DE5A018DEF24 Q41620644-B44D6BCA-9CDB-4314-B047-6F1C31924EF8 Q45869548-7DD793D1-AF58-44B2-B450-BBDE071568EC Q45872503-BED1E4DF-CAEE-4BD2-9D40-CD6AF250DC4F Q45883000-E441B1FC-890A-48B4-B913-CC39292B6C74 Q47350762-6EA16F5E-3DAB-4960-BA3B-55C87E21FCC3 Q48518084-E531E00A-5303-4C6F-86E1-36DC39164EC9 Q49752171-75CE428D-9653-4EC6-A41E-570E0BDCB100 Q57094780-10D56D22-621A-441E-9111-2452606B69C6 Q57095004-333CB695-7045-4A1F-ABDD-09158A9CB604 Q58781583-99C34272-E74E-419A-A47D-4EA4D65B05ED

P2860

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

http://www.wikidata.org/entity/Q36193201

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@ast

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@en

type

label

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@ast

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@en

prefLabel

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@ast

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@en

P1433

Q36193201-E19EE37F-FAEB-4FC6-BCE1-9A7687A1857F

P1476

Q36193201-D7DAB3FC-2B02-4BB5-B285-DBCA3B55D26E

P2093

Q36193201-14039FFD-0C94-42DB-8F6E-9048E3C628B0

Q36193201-26D02BB3-EDE2-4E32-A811-B6FCB001873B

Q36193201-2832A13F-B20A-4C9F-9547-C0BB37E036E4

Q36193201-63F124F2-AC18-4F6F-A029-E0F0ED962073

Q36193201-6E5803FA-325F-4F6A-9BA7-37DE03461619

Q36193201-714BDE2D-78BD-47D7-A5E8-D67BB24E48F7

Q36193201-74440F8E-981A-479E-8922-ED6732ADA8DD

Q36193201-86A6DCDC-0F3D-4D24-A8F5-0342C39C6BC2

Q36193201-970E5B11-834A-4AE1-BB28-FA008C60B304

Q36193201-A04735E3-1687-4E90-A295-C424CDE24948

P2860

Q36193201-0228FF1F-2BAD-41B9-8831-364029DB78D1

Q36193201-039DB5AE-86C2-4D13-BEC1-1DD557A293FA

Q36193201-04945929-3B96-4010-91A1-1C2AB0C71E5F

Q36193201-1054C816-1ECF-464D-A084-C6394FB277F5

Q36193201-1C0BE211-ED3C-424A-8BA5-ADF119EE7622

Q36193201-1E65E78C-8E32-4F14-A94B-5F41199D3E2C

Q36193201-3EF4674F-9CFB-4983-A6F9-9E2B88DE8BD9

Q36193201-4618B71B-412E-44C4-A9EA-E565BF79BBF5

Q36193201-4656662B-E2DD-443F-AA71-97093055690C

Q36193201-48ED4EB9-8AD3-40EA-B07E-6DE4B8A382A8

P304

Q36193201-E156D16E-83BB-4C71-926A-BB923F97CD82

P31

Q36193201-66D31D0D-382F-4ED9-809E-FB1A07DE7A60

P356

Q36193201-E08ED87E-34DF-45AD-93B9-21B001EA39FF

P407

Q36193201-FCC25F9B-B2F4-455D-B6C3-13FA3D2C871E

P433

Q36193201-A6A7D505-4EEC-40EE-AF89-BE61F557B301

P478

Q36193201-C70E467C-D717-47BF-B7D2-98376DB76712

P577

Q36193201-0122CFCB-1ECC-42F8-9B92-1D48A994ADF8

P5875

Q36193201-C378864A-0BD5-4E6B-8653-A112561B0E4E

P698

Q36193201-A02047BF-7089-4151-BCC0-1E0F5A9308C6

P932

Q36193201-03646318-F2D3-4085-A57C-1581B99AFF88

P356

BLOOD-2015-02-629873

P1433

P1476

Hemostatic efficacy, safety, a ...... severe von Willebrand disease

@en

P2093

Borislava G Pavlova

http://www.w3.org/2001/XMLSchema#string

Bruce Ewenstein

http://www.w3.org/2001/XMLSchema#string

Frank W G Leebeek

http://www.w3.org/2001/XMLSchema#string

Giancarlo Castaman

http://www.w3.org/2001/XMLSchema#string

Isabella Presch

http://www.w3.org/2001/XMLSchema#string

Jerzy Windyga

http://www.w3.org/2001/XMLSchema#string

Joan C Gill

http://www.w3.org/2001/XMLSchema#string

Margaret Ragni

http://www.w3.org/2001/XMLSchema#string

Miranda Chapman

http://www.w3.org/2001/XMLSchema#string

Ortrun Obermann-Slupetzky

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemistry and genetics of von Willebrand factor

Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor

Recombinant von Willebrand factor: potential therapeutic use.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

Treatment of von Willebrand's Disease.

Structure of the gene for human von Willebrand factor.

Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening.

Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.

Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.

P304

2038-2046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-02-629873

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280694136

http://www.w3.org/2001/XMLSchema#string

P698

26239086

http://www.w3.org/2001/XMLSchema#string

P932

4616237

http://www.w3.org/2001/XMLSchema#string